$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

$SAVA , VERA announced positive phase 2b results meeting primary end point.

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients

Phase 2/3 is expected to be positive.

$SRNE https://www.youtube.com/watch?v=n6_Ypx6soYQ great product, great clinical results .. expect a new ATH from Scilex this week!

Ji announced favorable phase 3 results in December 2021.

The results have been so good OVYDSO leapt from phase 1 to phase 3.

Also Zero Adverse Effects during Trial 👌.

phase 2/3 ready Each one is a potential all-star.

More then enough to cover SRNE trials for many years.

Sofusa/Enbrel trial was nothing short of incredible 10/10 response is previous NON-RESPONDERS at 50% the previous does.

$SRNE tomorrow great news about CoviMark, Virex, Phase 2 Mpro trial, Semdexa NDA, Abivertinib China/US, MSC trials in US/Brazil, Socazolimab NDA someone bought 1 million shares AH ✅

$SRNE me when we get that positive clinic trials news 😂

$MDGL this is the cream of the crop, we already have stellar phase 3 results in the books.

$MDGL nice opportunity to add a few hundred shares here 😆 the celebration of shorts today reminded me when the stock price dropped sharply by 27% in a couple of days before trial readout.

This is an outstanding setup for $VKTX's VK2809 P2b study which is scheduled to release data in Q2 2023.

Bullish going into Phase 3 next week!

$VKTX from what I've read from the preliminary trial data, the molecule is good, maybe better than $MDGL and has applications in weightloss.

Based on my multi year knowledge in NASH field, mdgl management so far did the best execution of clinical development - too many things to exemplify here!

Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.

After reaching its endpoints on its Phase 3 data we have seen a $240 spike!

Plus, remember this company is light years ahead of its competitors none of whom have had success with Phase 3. Bullish!

$VKTX Truth: VKTX increased more than 100% last 3 days since $MDGL has Phase 3 results.